New combo attack on pancreatic cancer: targeted pill meets chemo
NCT ID NCT06892054
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early-phase trial tests whether adding the targeted drug sotorasib (Lumykras) to standard chemotherapy is safe for people with advanced pancreatic cancer that has a specific KRAS G12C mutation. About 15 participants will receive the combination as their first treatment. The main goal is to check for side effects, with a secondary look at how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Sotorasib (Lumykras) combined with chemotherapy (gemcitabine/nab-paclitaxel or mFOLFIRINOX)
- What this could lead to
- If it works, this could point toward a new treatment option for people with a specific genetic type of advanced pancreatic cancer.
- What could go wrong
- This is a very early Phase 1 trial with only 15 people, focused on safety. It may not show enough benefit to move forward, and combining drugs could increase side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Chu Besançon - Hôpital Jean Minjoz
NOT_YET_RECRUITINGBesançon, France, France
-
Chu Bordeaux - Hôpital Haut Lévêque
NOT_YET_RECRUITINGPessac, France, France
-
Chu Brest - Hôpital Morvan
NOT_YET_RECRUITINGBrest, France, France
-
Chu Poitiers
NOT_YET_RECRUITINGPoitiers, France, France
-
Chu Reims - Hôpital Robert Debré
NOT_YET_RECRUITINGReims, France, France
-
Chu Toulouse
NOT_YET_RECRUITINGToulouse, France, France
-
Chu de Lille - Claude Huriez
NOT_YET_RECRUITINGLille, France, France
-
Complejo Hospitalario Regional de Málaga
RECRUITINGMálaga, Málaga, Spain
-
Complejo Hospitalario de Navarra
RECRUITINGPamplona, Navarre, Spain
-
Complexo Hospitalario Universitario de Ourense
RECRUITINGOurense, OURENSE, Spain
-
Hospital Clínic
RECRUITINGBarcelona, Barcelona, Spain
-
Hospital Clínico San Carlos
RECRUITINGMadrid, Madrid, Spain
-
Hospital General Universitario Gregorio Marañón
RECRUITINGMadrid, Madrid, Spain
-
Hospital General Universitario de Valencia
RECRUITINGValencia, Valencia, Spain
-
Hospital Reina Sofía
RECRUITINGCórdoba, Córdoba, Spain
-
Hospital Universitari Vall D'Hebron
RECRUITINGBarcelona, Barcelona, Spain
-
Hospital Universitario 12 de Octubre
RECRUITINGMadrid, Madrid, Spain
-
Hospital Universitario Central de Asturias
RECRUITINGOviedo, Principality of Asturias, Spain
-
Hospital Universitario Donostia-Donostia Unibertsitate Ospitalea
RECRUITINGDonostia / San Sebastian, Guipúzcoa, Spain
-
Hospital Universitario Marqués de Valdecilla
RECRUITINGSantander, Cantabria, Spain
-
Hospital Universitario Miguel Servet
RECRUITINGZaragoza, Aragon, Spain
-
Hospital Universitario de Salamanca
RECRUITINGSalamanca, SALAMANCA, Spain
-
Hôpital Léon Berard
NOT_YET_RECRUITINGLyon, France, France
-
Hôpital Paul-Brousse
NOT_YET_RECRUITINGVillejuif, France, France
-
Institut Català D'Oncologia L'Hospitalet (Ico)
RECRUITINGBarcelona, Barcelona, Spain
-
Sainte Catherine - Institut Avignon Provence
NOT_YET_RECRUITINGAvignon, France, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a pill rouse the immune system against pancreatic cancer?
- A sound wave that could expose hidden pancreatic cancer?
- Can a Two-Target antibody shrink Hard-to-Treat cancers?
- Targeted chemotherapy pump takes fight directly to pancreatic cancer liver tumors
- Light-Activated therapy targets pancreatic tumors during surgery
- Engineered immune cells take aim at Mesothelin-Positive tumors